Introduction
Prolactinoma is a type of pituitary adenoma, meaning a usually benign tumor arising from the pituitary gland that produces excess prolactin. Diagnosis is typically made by combining a blood test showing elevated prolactin with imaging of the pituitary, most often magnetic resonance imaging (MRI). Accurate diagnosis matters because prolactinoma can affect reproductive function, sexual function, bone health, and, in some cases, vision or brain structures if the tumor is large. It is also important to distinguish a prolactinoma from other causes of high prolactin, since management depends on the underlying cause.
Recognizing Possible Signs of the Condition
The first clues often come from symptoms related to prolactin excess and, in larger tumors, the physical effects of a growing mass in the pituitary region. In women, the condition may present with irregular menstrual periods or absent periods, infertility, or galactorrhea, which is milk discharge from the breasts unrelated to pregnancy or breastfeeding. In men, common findings include reduced libido, erectile dysfunction, infertility, and sometimes breast enlargement. Because prolactin suppresses the reproductive hormone pathway, these symptoms reflect reduced gonadotropin signaling rather than the tumor causing a direct local effect.
Some people have no obvious symptoms and are diagnosed after routine bloodwork or evaluation for another problem. When the tumor is larger, it may press on nearby structures and cause headaches or visual changes, especially loss of side vision due to compression of the optic chiasm. In children and adolescents, delayed puberty or growth concerns may also prompt evaluation, although prolactinomas are less common in this age group.
Medical History and Physical Examination
Diagnosis begins with a careful medical history. Clinicians ask about menstrual patterns, fertility concerns, sexual symptoms, breast discharge, headaches, vision changes, pregnancy history, and medication use. A detailed medication review is essential because several drugs can raise prolactin levels, particularly certain antipsychotics, some antidepressants, metoclopramide, and opioids. Doctors also ask about liver or kidney disease, thyroid symptoms, chest wall irritation, and recent stressors, since these can influence prolactin levels or mimic parts of the presentation.
The physical examination is focused on signs that may suggest hormone imbalance or tumor mass effect. The clinician may look for breast discharge, evidence of low estrogen or low testosterone, body hair changes, and signs of delayed puberty. Neurologic and eye examination can assess visual fields and other cranial nerve findings if a larger lesion is suspected. In many cases, the physical exam is not diagnostic on its own, but it helps determine which tests are needed and whether the prolactin elevation is likely to reflect a pituitary tumor versus another cause.
Diagnostic Tests Used for Prolactinoma
The main laboratory test is a serum prolactin level. A clearly elevated prolactin concentration raises suspicion for prolactinoma, but the interpretation depends on the degree of elevation and the clinical context. Mild to moderate elevations can occur for many reasons besides a prolactin-secreting tumor, while very high levels are more suggestive of prolactinoma, especially when imaging shows a compatible pituitary lesion. Because prolactin secretion can vary, doctors may repeat the test if the result is unexpected or if stress, recent exercise, breast stimulation, or sleep timing may have influenced it.
Laboratory evaluation usually also includes tests that look for other causes of high prolactin and assess pituitary function. Thyroid-stimulating hormone and free thyroxine are checked because primary hypothyroidism can increase prolactin through increased thyrotropin-releasing hormone signaling. Kidney and liver function tests may be ordered because impaired clearance or chronic systemic disease can contribute to elevated prolactin. In reproductive-age patients, pregnancy testing is commonly done because pregnancy is a physiologic cause of prolactin elevation. Additional pituitary hormones such as luteinizing hormone, follicle-stimulating hormone, estradiol, testosterone, insulin-like growth factor 1, adrenocorticotropic hormone, and morning cortisol may be measured if broader pituitary dysfunction is suspected.
Imaging is the key structural test. MRI of the pituitary with contrast is the preferred study because it provides detailed views of the gland, the sella turcica, and surrounding structures. MRI can identify a microadenoma, typically less than 10 mm, or a macroadenoma, 10 mm or larger. It also helps show whether the tumor extends beyond the pituitary, compresses the optic chiasm, or invades adjacent tissue. In some situations, if MRI is not possible, a CT scan may be used, but it is less sensitive for small pituitary lesions.
Functional evaluation may be used to assess the effect of the tumor on vision and pituitary hormone output. Formal visual field testing is important if the lesion is large or if the patient has visual complaints, because optic chiasm compression can produce peripheral field loss before obvious symptoms are noticed. Endocrine testing evaluates whether the tumor is only secreting prolactin or is also disrupting production of other pituitary hormones. This distinction matters because a large pituitary mass can cause both hypersecretion and hormone deficiency at the same time.
Tissue examination is rarely needed to diagnose prolactinoma before treatment. Most cases are identified using prolactin measurement and MRI rather than biopsy. Histologic confirmation occurs only if tissue is obtained during surgery, usually when the diagnosis is uncertain, the tumor does not respond as expected to medical therapy, or surgery is performed for mass effect. In pathology, the tumor cells may stain positive for prolactin and show features consistent with a pituitary adenoma. In routine practice, however, surgery is not required simply to confirm the diagnosis.
One additional laboratory issue is the hook effect, a pitfall in prolactin measurement. In very large tumors, prolactin can sometimes be falsely read as only mildly elevated because extremely high hormone levels saturate the assay. If a large pituitary mass is present but the prolactin level seems too low for the size of the lesion, the laboratory may repeat the test using dilution to reveal the true concentration.
Interpreting Diagnostic Results
Doctors interpret prolactin results in combination with the tumor size and the rest of the clinical picture. A markedly elevated prolactin level together with a pituitary lesion on MRI strongly supports prolactinoma. Very high prolactin concentrations are more typical of prolactin-secreting tumors than of simple stalk compression from another mass. By contrast, a pituitary lesion with only modest prolactin elevation may represent a nonfunctioning adenoma that is interrupting dopamine delivery to the pituitary stalk, because dopamine normally inhibits prolactin release.
Interpretation also depends on whether other causes of hyperprolactinemia have been excluded. If medication use, pregnancy, hypothyroidism, renal disease, or chest wall stimulation explains the result, the diagnosis may be something other than prolactinoma. When MRI shows no pituitary mass and prolactin elevation is mild, clinicians usually search for secondary causes rather than label the patient as having a tumor.
In macroprolactinomas, prolactin levels are often much higher than in microprolactinomas, but the exact number does not always predict behavior perfectly. The relationship between tumor size and prolactin level helps, yet clinicians also consider symptom severity, pituitary function, and whether the lesion responds to dopamine agonist therapy. Response to treatment can support the diagnosis, but treatment response alone does not replace initial diagnostic evaluation.
Conditions That May Need to Be Distinguished
Several conditions can cause elevated prolactin or symptoms similar to those of prolactinoma. Physiologic causes include pregnancy and breastfeeding. Pathologic but non-tumor causes include primary hypothyroidism, chronic kidney disease, cirrhosis, seizures, chest wall trauma, and significant stress. Drug-induced hyperprolactinemia is especially important because medications that block dopamine signaling can raise prolactin substantially and produce menstrual or sexual symptoms.
Other pituitary masses must also be considered. A nonfunctioning pituitary adenoma can compress the pituitary stalk and cause elevated prolactin without being a prolactinoma. Craniopharyngioma, Rathke cleft cyst, meningioma, and inflammatory lesions of the sellar region may create similar imaging findings or symptoms from mass effect. A pituitary hyperplasia, rather than a true tumor, can sometimes enlarge the gland in response to endocrine signals, such as in untreated hypothyroidism.
Doctors differentiate these conditions by examining the pattern of hormone levels, the degree of prolactin elevation, MRI characteristics, and whether the lesion behaves like a prolactin-producing tumor. When the prolactin level is much higher than expected for a stalk effect lesion, prolactinoma becomes more likely. When the level is only slightly elevated and another cause is present, the diagnosis should be reconsidered.
Factors That Influence Diagnosis
Age and sex influence both the likelihood of diagnosis and how it is recognized. In women of reproductive age, menstrual disruption is often the initial clue. In men, diagnosis is sometimes delayed because symptoms such as reduced libido or erectile dysfunction are less specific and may be attributed to other causes. In postmenopausal women, a prolactinoma may remain hidden longer because menstrual changes are no longer available as a warning sign.
Tumor size also affects the diagnostic pathway. Small tumors may cause only hormonal symptoms and be found after targeted laboratory testing, while larger tumors are more likely to cause headaches, vision changes, or multiple pituitary hormone abnormalities. Large tumors also create more risk of assay pitfalls such as the hook effect, which means laboratories may need to repeat prolactin testing with dilution.
Pregnancy, thyroid disease, renal dysfunction, liver disease, and use of dopamine-blocking medications can all alter the interpretation of prolactin levels. For that reason, diagnosis is rarely based on one isolated result. Clinicians integrate laboratory data, imaging findings, symptoms, and alternative explanations before confirming prolactinoma. In complex cases, consultation with an endocrinologist is often helpful.
Conclusion
Prolactinoma is diagnosed through a structured process that combines symptom review, focused examination, hormone testing, and pituitary imaging. Elevated prolactin is the central laboratory clue, but it must be interpreted carefully because many non-tumor conditions can raise the hormone. MRI of the pituitary helps confirm the presence, size, and extent of a lesion, while visual field testing and broader pituitary hormone studies assess the tumor’s effects on surrounding structures and endocrine function. In unusual cases, pathology provides confirmation, though this is not usually required. Accurate diagnosis depends on matching the biological pattern of prolactin excess with imaging and excluding other causes that can produce similar findings.